The page is the record's research on the issuer — no analyst, no rating, no view. # Quantum Biopharma Ltd. (NASDAQ: QNTM) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Quantum Biopharma Ltd., listed on NASDAQ under ticker QNTM, with ISIN US74764Y2054. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-A6. The security type is Non-operating entity type (other), the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Ontario, Canada. The listing status is listed, not halted. ## The disclosure read The record holds 42 filings in the twelve months to 2026-11-08, across 33 filing days. The filings are 38 results, 3 regulatory filings and 1 prospectus. The median gap between filing days is 4.5 days, and the latest filing is 3 days before the record date. The latest filing is a results filing dated 2026-11-05. The NASDAQ medians are 52 filings, a cadence gap of 6.0 days and a latency of 5.0 days across 4359 issuers. The 2834 Pharmaceutical Preparations sector medians are 63.0 filings, a cadence gap of 6.0 days and a latency of 4.0 days across 526 issuers. The issuer's 42 filings are below both medians, its cadence gap of 4.5 days is below both, and its latency of 3 days is below both. ## Auditor The auditor of record is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and foreign private issuers and older filings carry none. The auditor's location is not on the record. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change events. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted. ## Orderability The outcome is not determinable under acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, as the chapter's orderability section carries no client categories and the outcome cannot name its client category. The chapter is as of 2026-11-04. ## Coverage The record finds 3 research houses named on the issuer's investor-relations page: Rodman & Renshaw, Kingswood Capital Partners and Singular Research. ## Open research The record finds no openly published research notes on the issuer. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The record holds the issuer's sealed years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001771885.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/QNTM (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://www.quantumbiopharma.com/investors (coverage) - https://mcp.us-cm-kg.ai/record/NASDAQ/QNTM (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/QNTM · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp